MDI-0238 (MOD-B)
Mast cell-mediated diseases (e.g., chronic urticaria, anaphylaxis)
PreclinicalActive
Key Facts
Indication
Mast cell-mediated diseases (e.g., chronic urticaria, anaphylaxis)
Phase
Preclinical
Status
Active
Company
About Alivexis
Alivexis develops novel small-molecule drugs for cancer and inflammatory diseases using its proprietary computational drug discovery platform.
View full company profile